Introduction
EEG slowing is generally considered to indicate central nervous system (CNS) dysfunction, for example as the consequence of ischaemic, metabolic or toxic conditions. 1, 2 All medications that influence CNS can also lead to changes of EEG frequency, in particular of EEG background frequency. Background slowing can be used as a neurophysiological parameter of drug impact on cerebral functions. 3 Antiepileptic drugs (AEDs) are among the most widely prescribed CNS active medications. The fact that most patients remain on therapy for many years and often for a lifetime, emphasises the need to focus on long-term adverse effects of these drugs. Alteration of cognitive functions is one of the major factors influencing quality of life in patients with epilepsy. 4, 5 Neuropsychological testing has been the preferred method of examining cognitive functions related to the use of AEDs but it has a number of methodological problems, for example a significant test-retest variability or a low specificity (the results may be influenced by other factors such as mood, anxiety, less sleep, pain). 5 The established sensitivity of EEG to antiepileptic drugs made that EEG has become useful as an objective measure for monitoring chronic AED therapy and in investigation of cognitive functions. 6, 3 The EEG effects of older, classical AEDs are well known: a stable therapy with, for example, Phenytoin (PHT), Carbamazepine (CBZ), Phenobarbital (PB) enhances a slow activity on EEG background rhythm (increase of theta and delta, decrease of alpha frequency) and the EEG changes correlate to changes on cognitive measures. [7] [8] [9] Within the last two decades several new AEDs have been introduced into clinical practice. Most of them are at least so effective as the old AEDs, but they seem to be better tolerated, in particular regarding cognitive functions than the old drugs. 10, 1 Recent studies have also examined the EEG effect of the new AEDs-it seems to be milder and less consistent than that caused by old AEDs. For example, lamotrigine with no or minimal cognitive side effect does not induce EEG background slowing. 11 On the other side topiramate, that is known for its neurotoxic adverse effects, increase slow, theta and delta and decrease rapid frequencies within alpha and beta band. 
Summary:
The EEG background activity reflects the functional state of the brain. The established sensitivity of EEG to drug intoxication and in particular to antiepileptic drugs (AEDs) made that EEG has become useful as an objective measure for monitoring chronic AED therapy and in investigation of cognitive functions. Therapy with classical AEDs has become associated with slowing of EEG background rhythm and the EEG changes correlated to changes on cognitive measures. So far, it has not been tested whether the relatively new AED, levetiracetam (LEV) has a detrimental effect on the EEG background frequencies, too. Methods: During the time of 6 months 28 patients underwent EEG-recording and neuropsychological testing at the three timepoints: before initiating LEV therapy, after 2 months and again after 4 months after achieving plateau dosing of LEV. EEG background frequency was analysed by using the fast Fourier Transform (FFT).
Results: The titration and the following treatment with LEV add-on showed no negative effect on any of the measures analysed. In particular it did not lead to the lower peak frequency within the alpha band, it neither decreased the percentage of alpha band nor increase the percentage of theta and delta band. In addition there could be noticed an increase of the percentage of beta band.
Conclusions: Our findings demonstrate, that a LEV add-on therapy is not associated with a slowing of the EEG background frequency. This is in accordance with neuropsychological reports of our own lab and others showing that LEV add-on therapy has no negative effects on cognitive functions, either. ß 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Levetiracetam (LEV) is a new antiepileptic drug, introduced into the clinical practice in Europe for about 8 years. This drug is known for its favourable neuropsychological profile, but it can also cause adverse behavioural side effects such as adynamia or aggression. 14, 15 In contrast to other new AED, the impact of LEV on the EEG background activity has not been investigated so far. The subjects that have been included to the following study underwent a neuropsychological testing before and during the LEV therapy, prior to the performed EEG. Thereby no cognitive deficits could be observed; moreover, some of the functions, for example learning and language understanding, demonstrated significant benefits in the course of LEV therapy. 16 We raised the question, whether neurophysiologic parameters would reflect these positive cognitive results observed under LEV therapy. We analysed the effect of LEV on different EEG frequencies.
Methods

Patients
Twenty-eight consecutive unselected patients with pharmacoresistent epilepsy were recruited from the outpatient clinic from the Epilepsy Center Berlin Brandenburg, Teaching Hospital of the Humboldt University, Berlin (Table 1) . At the beginning of the study they had a stable basic co-medication with an AED (except of 3 patients that were untreated at the entry), to which in the course of the study LEV was added.
In this study we included the 22 patients with monotherapy at the beginning.
During the individual study period of 6 months patients underwent EEG-recording and neuropsychological testing at three timepoints: T1, before initiating LEV therapy (baseline); T2, two months after the initiation of therapy and achieving the end-dose (titration phase); T3, four months after achieving plateu dosing of LEV (plateu phase). The end-dose was adjusted for each patient individually, depending on seizure control and tolerability and was between 1000 and 3000 mg/day. The co-medication remained unchanged during the entire study.
Procedure
EEG-recordings were held after neuropsychological testing at rest with closed eyes at 2:00 p.m. The whole recordings were obtained over 4-6 min. We attempted to maintain subjects in an alert but relaxed state (simple mental activation is the best condition for EEG background rhythm), so during the registration they were asked for two minutes a few simple questions. For the study we considered this 2-min-activation-phase only.
EEG was recorded with golden electrodes placed according to the international 10-20-system at F7, F8, T3, T4, T5, T6, O1, and O2. Electrode impedances was less than 5 kV.
In 15 patients EEG-recording was performed at three points (T1, T2, and T3); in 7 patients only twice (T1 and T2).
The occipital EEG rhythms from each record were investigated by means of quantitative analysis, using the fast Fourier Transform (FFT).
For further EEG processing we chose the methods that have been proposed and published by Salinsky et al. 17 Prior to analysis the 2-min-segments of activation EEG were selected. The EEG segments with artifacts or with interictal epileptiform activity (Spikes or Sharp waves) were eliminated. Thirty 4-s epochs of EEG (120 s of activation) were analysed by using the FFT. In order to minimize the statistical variables, the analysis was limited to the O1 and O2 electrodes, and the results from both were averaged.
The following parameters from the FFT were considered: (a) peak frequency within the alpha band; (b) percentage of total power (relative power) within the alpha band; (c) percentage of total power within the theta band; (d) percentage of total power within the delta band; (e) percentage of total power within the beta band.
Statistics
A Friedman test was used to compare the quantitative EEG measures in the group of patients, who underwent EEG-recordings at the three timepoints (T1, T2, and T3).
A Wilcoxon test was used for pair comparisons of EEG results between the three timepoints.
A p-value <0.05 was considered significant. All procedures were performed with SPSS 11.
Results
The results show that a titration and than a 6-month treatment with LEV add-on therapy did not lead to slowing of EEG rhythms over occipital regions.
Within the analysed parameters we observed:
(a) no decrease in peak alpha frequency, no lower percentage of total power within the alpha band after initiating and in course of LEV therapy. There was an upward tendency of maximal alpha frequency within the analysed three timepoints, which was statistically not significant. (b) no power increase within the slower, theta and delta activities. (c) an increase of percentage within the faster, beta frequency, which was statistically significant (p = 0.027 at p < 0.05).
The following study demonstrates that the therapy with LEV exert no negative effect on any of the measures analysed. The results for each of the analysed parameter are presented in Table 2 . The graphic presentation of the results follows in Fig. 1 .
Discussion
Our study is the first to investigate the impact of LEV add-on therapy on EEG background frequency. So far, it has not been tested whether the titration and the following therapy with LEV induces changes, in particular slowing of EEG background.
The findings from our study demonstrate that a LEV add-on therapy have no negative effect on EEG frequencies over occipital region. We did not find a slowing of occipital frequency: in the course of LEV therapy it came neither to decrease of alpha frequency nor to increase of theta and delta activity.
The results from our quantitative EEG analyse are comparable with these, that were reported under a LTG therapy. Both medications did not lead to EEG changes within the alpha, theta and delta band, but increased the percentage of beta band. Both medications belong to AEDs which do not induce cognitive dysfunctions. 11, 18 The relationship between EEG and mental processes is a complex problem. The systemic studies in particular of Salinsky et al., Meador et al., Herkes et al., Frost et al. demonstrated an association between the elecktoencephalographical changes (in particular of EEG background rhythm) and the changes in cognitive functions. 1, 6, 7, 19 There have been reported a positive correlation between the slowing of EEG background rhythm and the negative neuropsychological results on the cognitive test batteries: greater the EEG slowing, greater the cognitive dysfunction and subjective neurotoxicity. In addition, Salinsky et al. have demonstrated that the EEG slowing could better reflect the AED-induced subjective neurotoxicity than the objective cognitive test batteries.
As mentioned above the electrophysiological impact of LTG and LEV is different than that caused by classical AEDs. According to Marciani et al. the LTG induced increase of faster EEG activity could be indicative of a positive drug role in attentional processes. 18 For
Neufeld et al. these EEG changes observed under LTG therapy were analogous to those of increased alertness on neuropsychological testing.
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The reports from our neuropsychological lab and the others indicated that LEV has no negative effects on cognitive functions. 16, 20 So far were our EEG results in accordance with the cognitive performances. Further, some of the cognitive functions on our testing showed improvements. Why we have not observed thereby an increase in the alpha activity, as could be eventual assumed? As Salinsky et al. have already reported there is no direct or casual relation between EEG background measures and cognitive functions 3 and the improvement of cognitive functions is not closely correlated to an increase of background frequency. The other possible explanation, could be the fact, that the all our patients were treated, beside LEV, with the other AED, so the pharmacokinetic interaction of co-medications could eventual inhibit the positive EEG effect of titrated LEV. It is known that the polytherapy and the high-dose of AEDs can exert greater EEG effect. Miyauchi et al. and Clemens et al. reported that the most marked EEG slowing by epileptic patients was in the polytherapy group, followed by the monotherapy group and then the untreated group. 21, 22 However, the fact that the untreated epilepsy group, compared to normal controls, also showed the background slowing suggests that not only AEDs can play here a role. It seems that the epilepsy per se may be also involved in the genesis of the EEG background slowing by patients with epilepsy. The factors that could be by this process relevant and contribute to EEG background abnormalities by epileptic patients are the presence of structural or functional brain, high frequency of seizures, seizure onset at young ages (0-5 years). 18, 20 Our study has several limitations. We have not had a control group. The sample of the patients was small and treated with different co-medications to which LEV was added. Different AEDs have different effects on EEG background frequency (as have been mentioned in the introduction), so this could false the ''real'' effect of LEV. This issue could be resolved by a LEV monotherapy study. During the performance of the present study, treatment with LEV was admitted only as an add-on therapy. In the meantime also a LEV monotherapy has been authorised in a clinical practice. The possible effects of a LEV monotherapy on EEG background frequency and cognition have to be determined.
Overall quantitative EEG analysis seems to be a simple, fast and reliable method to monitoring neurotoxicity and in investigation of cognitive functions. It is recommendable to use it more often in a clinical practice in patients on chronic AED therapy.
